Ascendant Dx Closes on $2M Financing to Develop Proteomic-based Breast Cancer Test | GenomeWeb

NEW YORK (GenomeWeb) – Proteomics-based diagnostics firm Ascendant Dx today said that it closed on a $2 million funding round, which will support clinical trials for and commercialization of its tears-based breast cancer detection test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.